Vanguard Group’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-5,706,695
| Closed | -$530M | – | 4666 |
|
|
2021
Q4 | $530M | Buy |
5,706,695
+52,715
| +0.9% | +$3.47M | 0.01% | 964 |
|
|
2021
Q3 | $337M | Buy |
5,653,980
+33,511
| +0.6% | +$1.98M | 0.01% | 1247 |
|
|
2021
Q2 | $383M | Buy |
5,620,469
+29,444
| +0.5% | +$1.92M | 0.01% | 1167 |
|
|
2021
Q1 | $388M | Buy |
5,591,025
+327,186
| +6% | +$25.2M | 0.01% | 1115 |
|
|
2020
Q4 | $404M | Buy |
5,263,839
+140,792
| +3% | +$10.6M | 0.01% | 1002 |
|
|
2020
Q3 | $383M | Sell |
5,123,047
-24,659
| -0.5% | -$1.64M | 0.01% | 895 |
|
|
2020
Q2 | $324M | Buy |
5,147,706
+432,071
| +9% | +$23.8M | 0.01% | 983 |
|
|
2020
Q1 | $198M | Buy |
4,715,635
+158,872
| +3% | +$7.28M | 0.01% | 1140 |
|
|
2019
Q4 | $207M | Sell |
4,556,763
-18,072
| -0.4% | -$854K | 0.01% | 1371 |
|
|
2019
Q3 | $209M | Buy |
4,574,835
+23,337
| +0.5% | +$1.31M | 0.01% | 1301 |
|
|
2019
Q2 | $267M | Sell |
4,551,498
-6,341
| -0.1% | -$328K | 0.01% | 1183 |
|
|
2019
Q1 | $204M | Sell |
4,557,839
-133,628
| -3% | -$6.13M | 0.01% | 1325 |
|
|
2018
Q4 | $183M | Buy |
4,691,467
+21,687
| +0.5% | +$851K | 0.01% | 1296 |
|
|
2018
Q3 | $215M | Buy |
4,669,780
+130,019
| +3% | +$5.27M | 0.01% | 1335 |
|
|
2018
Q2 | $198M | Buy |
4,539,761
+285,683
| +7% | +$12.3M | 0.01% | 1353 |
|
|
2018
Q1 | $168M | Buy |
4,254,078
+1,049,483
| +33% | +$40.8M | 0.01% | 1406 |
|
|
2017
Q4 | $109M | Buy |
3,204,595
+47,086
| +1% | +$1.34M | ﹤0.01% | 1662 |
|
|
2017
Q3 | $80.5M | Buy |
3,157,509
+684,234
| +28% | +$15.7M | ﹤0.01% | 1819 |
|
|
2017
Q2 | $41.7M | Buy |
2,473,275
+482,736
| +24% | +$6.62M | ﹤0.01% | 2099 |
|
|
2017
Q1 | $29.1M | Buy |
1,990,539
+91,043
| +5% | +$1.35M | ﹤0.01% | 2268 |
|
|
2016
Q4 | $27M | Buy |
1,899,496
+49,208
| +3% | +$762K | ﹤0.01% | 2272 |
|
|
2016
Q3 | $32.4M | Buy |
1,850,288
+23,085
| +1% | +$383K | ﹤0.01% | 2133 |
|
|
2016
Q2 | $31.2M | Buy |
1,827,203
+125,545
| +7% | +$2.24M | ﹤0.01% | 2122 |
|
|
2016
Q1 | $33.5M | Sell |
1,701,658
-14,606
| -0.9% | -$234K | ﹤0.01% | 2057 |
|
|
2015
Q4 | $32.6M | Buy |
1,716,264
+48,587
| +3% | +$991K | ﹤0.01% | 2092 |
|
|
2015
Q3 | $31.9M | Buy |
1,667,677
+38,007
| +2% | +$1.29M | ﹤0.01% | 2073 |
|
|
2015
Q2 | $75.6M | Buy |
1,629,670
+51,680
| +3% | +$2.24M | 0.01% | 1716 |
|
|
2015
Q1 | $69M | Buy |
1,577,990
+188,529
| +14% | +$8.76M | ﹤0.01% | 1754 |
|
|
2014
Q4 | $48.2M | Buy |
1,389,461
+68,822
| +5% | +$2.79M | ﹤0.01% | 1853 |
|
|
2014
Q3 | $55.3M | Sell |
1,320,639
-13,759
| -1% | -$614K | ﹤0.01% | 1738 |
|
|
2014
Q2 | $78.2M | Buy |
1,334,398
+9
| +0% | +$567 | 0.01% | 1574 |
|
|
2014
Q1 | $84.1M | Sell |
1,334,389
-62,060
| -4% | -$4.12M | 0.01% | 1462 |
|
|
2013
Q4 | $81.7M | Buy |
1,396,449
+83,764
| +6% | +$4.38M | 0.01% | 1454 |
|
|
2013
Q3 | $69.2M | Buy |
1,312,685
+46,123
| +4% | +$3.1M | 0.01% | 1501 |
|
|
2013
Q2 | $97.5M | Buy |
+1,266,562
| New | +$103M | 0.01% | 1181 |
|
Vanguard Group's ARNA Position: Q1 2022 in Review
Vanguard Group sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 5,706,695 shares — an estimated $530M sold.
Vanguard Group first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $530M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Vanguard Group reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Vanguard Group sold 5,706,695 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $530M.
- Vanguard Group first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Vanguard Group's Arena Pharmaceuticals Inc position peaked at $530M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Vanguard Group's 13F filing for Q1 2022, filed 13 May 2022.